Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PHVS | US
0.60
2.32%
Healthcare
Biotechnology
30/06/2024
09/03/2026
26.51
26.12
26.70
25.80
Pharvaris N.V. a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121 a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416 an on-demand rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719 a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands Switzerland and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden the Netherlands.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
33.7%1 month
32.5%3 months
46.8%6 months
62.7%-
-
3.17
0.00
0.00
-1.38
-
-
-116.10M
1.43B
1.43B
-
-
-
-
-45.05
5.12
1.97
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.95
Range1M
3.95
Range3M
5.84
Rel. volume
1.61
Price X volume
4.87M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | ANIP | Biotechnology | 74.81 | 1.57B | 1.04% | 50.68 | 68.04% |
| Ocular Therapeutix Inc | OCUL | Biotechnology | 9.94 | 1.55B | -3.21% | n/a | 19.83% |
| Ardelyx Inc | ARDX | Biotechnology | 6.17 | 1.45B | -0.32% | n/a | 71.36% |
| Intellia Therapeutics Inc | NTLA | Biotechnology | 13.89 | 1.41B | 3.35% | n/a | 10.95% |
| ELVN | ELVN | Biotechnology | 29.73 | 1.40B | 0.99% | n/a | 0.06% |
| Innoviva Inc | INVA | Biotechnology | 22.32 | 1.40B | 1.32% | 11.32 | 67.72% |
| Mineralys Therapeutics Inc. | MLYS | Biotechnology | 27.24 | 1.35B | 2.44% | n/a | 0.00% |
| Kodiak Sciences Inc | KOD | Biotechnology | 25.72 | 1.35B | 3.46% | n/a | 81.94% |
| Immunome Inc | IMNM | Biotechnology | 21.33 | 1.28B | 1.38% | n/a | 1.09% |
| immatics biotechnologies GmbH | IMTX | Biotechnology | 10 | 1.19B | 1.42% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.07 | 1.41B | 1.22% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.22 | 1.14B | 1.06% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 35.25 | 1.02B | -2.87% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.39 | 783.29M | 1.89% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.31 | 729.29M | 0.16% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.37 | 682.35M | 0.37% | 42.05 | 64.69% |
| Ennis Inc | EBF | Building Products & Equipment | 21.16 | 550.24M | -0.70% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 25.67 | 513.16M | -0.39% | n/a | 1.50% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.67 | 351.58M | -6.14% | n/a | 174.23% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.47 | 337.11M | 1.49% | n/a | 3644.76% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.38 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.17 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 46.75 | 72.80 | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 1.43B | 3.66B | Emerging |